These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 8537378

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro.
    Karabina SA, Elisaf MC, Goudevenos J, Siamopoulos KC, Sideris D, Tselepis AD.
    Atherosclerosis; 1996 Aug 23; 125(1):121-34. PubMed ID: 8831934
    [Abstract] [Full Text] [Related]

  • 3. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein.
    Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM.
    J Biol Chem; 1999 Mar 12; 274(11):7018-24. PubMed ID: 10066756
    [Abstract] [Full Text] [Related]

  • 4. PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation.
    Dentan C, Lesnik P, Chapman MJ, Ninio E.
    Arterioscler Thromb; 1994 Mar 12; 14(3):353-60. PubMed ID: 8123638
    [Abstract] [Full Text] [Related]

  • 5. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.
    MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM.
    Biochem J; 1999 Mar 01; 338 ( Pt 2)(Pt 2):479-87. PubMed ID: 10024526
    [Abstract] [Full Text] [Related]

  • 6. Copper-catalyzed oxidation mediates PAF formation in human LDL subspecies. Protective role of PAF:acetylhydrolase in dense LDL.
    Tsoukatos DC, Arborati M, Liapikos T, Clay KL, Murphy RC, Chapman MJ, Ninio E.
    Arterioscler Thromb Vasc Biol; 1997 Dec 01; 17(12):3505-12. PubMed ID: 9437199
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
    Milionis HJ, Elisaf MS, Karabina SA, Bairaktari E, Tselepis AD, Siamopoulos KC.
    Kidney Int; 1999 Dec 01; 56(6):2276-85. PubMed ID: 10594806
    [Abstract] [Full Text] [Related]

  • 9. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.
    Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM.
    Proc Natl Acad Sci U S A; 1989 Apr 01; 86(7):2393-7. PubMed ID: 2928339
    [Abstract] [Full Text] [Related]

  • 10. High-density lipoprotein inhibits the production of platelet activating factor acetylhydrolase by HepG2 cells.
    Satoh K, Imaizumi T, Yoshida H, Takamatsu S.
    J Lab Clin Med; 1994 Feb 01; 123(2):225-31. PubMed ID: 8301198
    [Abstract] [Full Text] [Related]

  • 11. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase.
    Steinbrecher UP, Pritchard PH.
    J Lipid Res; 1989 Mar 01; 30(3):305-15. PubMed ID: 2723538
    [Abstract] [Full Text] [Related]

  • 12. Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein.
    Tsoukatos DC, Liapikos TA, Tselepis AD, Chapman MJ, Ninio E.
    Biochem J; 2001 Jul 15; 357(Pt 2):457-64. PubMed ID: 11439095
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor.
    Ambrosio G, Oriente A, Napoli C, Palumbo G, Chiariello P, Marone G, Condorelli M, Chiariello M, Triggiani M.
    J Clin Invest; 1994 Jun 15; 93(6):2408-16. PubMed ID: 8200975
    [Abstract] [Full Text] [Related]

  • 17. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase.
    Tsironis LD, Mitsios JV, Milionis HJ, Elisaf M, Tselepis AD.
    Cardiovasc Res; 2004 Jul 01; 63(1):130-8. PubMed ID: 15194469
    [Abstract] [Full Text] [Related]

  • 18. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme.
    Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E.
    Arterioscler Thromb Vasc Biol; 1995 Oct 01; 15(10):1764-73. PubMed ID: 7583554
    [Abstract] [Full Text] [Related]

  • 19. The contribution of individual lipoproteins to the degradation of platelet-activating factor in human serum.
    Ostermann G, Kostner GM, Gries A, Malle E, Till U.
    Haemostasis; 1989 Oct 01; 19(3):160-8. PubMed ID: 2744632
    [Abstract] [Full Text] [Related]

  • 20. Transfer of phospholipase A-resistant pyrene-dialkyl-glycerophosphocholine to plasma lipoproteins: differences between Lp[a] and LDL.
    Gorges R, Hofer G, Sommer A, Stütz H, Grillhofer H, Kostner GM, Paltauf F, Hermetter A.
    J Lipid Res; 1995 Feb 01; 36(2):251-9. PubMed ID: 7751812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.